Loading clinical trials...
Loading clinical trials...
Single-Shot Liposomal Bupivacaine vs. Liposomal Bupivacaine Combined With Dexamethasone Prior to Foot and Ankle Procedures: A Prospective Randomized Controlled Trial
This study aims to understand the ideal formulation to utilize in saphenous nerve and popliteal nerve blocks for foot and ankle procedures. It will examine the use of liposomal bupivacaine alone or liposomal bupivacaine with dexamethasone prior to foot and ankle procedures in peripheral nerve blocks. We will compare liposomal bupivacaine (Exparel) and liposomal bupivacaine (Exparel) combined with dexamethasone to determine if the addition of dexamethasone significantly decreases postoperative narcotic use and prolongs analgesic effects when administered in a popliteal and saphenous block prior to foot and ankle orthopedic procedures.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Rothman Orthopaedic Institute
Philadelphia, Pennsylvania, United States
Start Date
June 17, 2024
Primary Completion Date
June 30, 2025
Completion Date
June 30, 2025
Last Updated
June 20, 2024
126
ESTIMATED participants
Exparel 266 MG Per 20 ML Injection
DRUG
Bupivacaine Hcl 0.75% Inj
DRUG
Dexamethasone
DRUG
Lead Sponsor
Rothman Institute Orthopaedics
NCT07482709
NCT07041736
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07310953